{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:46:46Z","timestamp":1745419606203},"reference-count":31,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2017.7515","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T08:04:55Z","timestamp":1512461095000},"source":"Crossref","is-referenced-by-count":7,"title":["Prognostic relevance of FGFR2 expression in stage\u00ef\u00bf\u00bdII\/III gastric cancer with curative resection and S\u20111 chemotherapy"],"prefix":"10.3892","author":[{"given":"Kei","family":"Hosoda","sequence":"first","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ushiku","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ema","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Moriya","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mieno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Washio","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252\u20110374, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"key20200714001939_b1-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20200714001939_b2-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200714001939_b3-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20200714001939_b4-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200714001939_b5-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","article-title":"Emerging therapeutic targets in endometrial cancer","volume":"8","author":"Dedes","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200714001939_b6-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20200714001939_b7-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20200714001939_b8-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20200714001939_b9-ol-0-0-7515","doi-asserted-by":"crossref","unstructured":"HattoriYOdagiriHNakataniHMiyagawaKNaitoKSakamotoHKatohOYoshidaTSugimuraTTeradaMK-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genesProc Natl Acad Sci USA8759835987199010.1073\/pnas.87.15.59832377625","DOI":"10.1073\/pnas.87.15.5983"},{"key":"key20200714001939_b10-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br J Cancer"},{"key":"key20200714001939_b11-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study","volume":"110","author":"Su","year":"2014","journal-title":"Br J Cancer"},{"key":"key20200714001939_b12-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","article-title":"Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20200714001939_b13-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-10-1489","article-title":"GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling","volume":"70","author":"Bai","year":"2010","journal-title":"Cancer Res"},{"key":"key20200714001939_b14-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res"},{"key":"key20200714001939_b15-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.18632\/oncotarget.2987","article-title":"Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"key20200714001939_b16-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"key20200714001939_b17-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1535-7163.MCT-14-0255","article-title":"Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification","volume":"13","author":"Kim","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20200714001939_b18-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Xie","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20200714001939_b19-ol-0-0-7515","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/abbs\/gmv103","article-title":"HER3\/ErbB3, an emerging cancer therapeutic target","volume":"48","author":"Zhang","year":"2016","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"key20200714001939_b20-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/cgt.2008.15","article-title":"The ERBB3 receptor in cancer and cancer gene therapy","volume":"15","author":"Sithanandam","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"key20200714001939_b21-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1111\/j.1349-7006.2010.01640.x","article-title":"Significance of integrin \u03b1v\u03b25 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin","volume":"101","author":"Yoshioka","year":"2010","journal-title":"Cancer Sci"},{"key":"key20200714001939_b22-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/cas.12556","article-title":"Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer","volume":"105","author":"Ema","year":"2014","journal-title":"Cancer Sci"},{"key":"key20200714001939_b23-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s101200050051","article-title":"Japanese classification of gastric carcinoma-2nd english edition","volume":"1","author":"Japanese Gastric Cancer Association","year":"1998","journal-title":"Gastric Cancer"},{"key":"key20200714001939_b24-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","article-title":"Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma","volume":"18","author":"Nagatsuma","year":"2015","journal-title":"Gastric Cancer"},{"key":"key20200714001939_b25-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12957-016-1081-4","article-title":"Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer","volume":"15","author":"Inokuchi","year":"2017","journal-title":"World J Surg Oncol"},{"key":"key20200714001939_b26-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-07-5229","article-title":"FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival","volume":"68","author":"Kunii","year":"2008","journal-title":"Cancer Res"},{"key":"key20200714001939_b27-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2445::AID-CNCR5>3.0.CO;2-L","article-title":"Prediction of early and late recurrence after curative resection for gastric carcinoma","volume":"77","author":"Adachi","year":"1996","journal-title":"Cancer"},{"key":"key20200714001939_b28-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000320691","article-title":"Predictors of timing and patterns of recurrence after curative resection for gastric cancer","volume":"27","author":"Eom","year":"2010","journal-title":"Dig Surg"},{"key":"key20200714001939_b29-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5230\/jgc.2011.11.1.46","article-title":"Clinicopathologic characteristics of gastric cancer patients according to the timing of the recurrence after curative surgery","volume":"11","author":"Choi","year":"2011","journal-title":"J Gastric Cancer"},{"key":"key20200714001939_b30-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20200714001939_b31-ol-0-0-7515","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/mmi.13707","article-title":"Subversion of host kinases: A key network in cellular signaling hijacked by Helicobacter pylori CagA","volume":"105","author":"Tegtmeyer","year":"2017","journal-title":"Mol Microbiol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T22:23:19Z","timestamp":1660083799000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.7515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":31,"URL":"https:\/\/doi.org\/10.3892\/ol.2017.7515","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}